ARS Pharmaceuticals shares are trading lower after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $30.
Portfolio Pulse from Benzinga Newsdesk
ARS Pharmaceuticals shares declined after Cantor Fitzgerald initiated coverage with an Overweight rating and set a price target of $30.
August 21, 2024 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ARS Pharmaceuticals (SPRY) shares fell following Cantor Fitzgerald's initiation of coverage with an Overweight rating and a $30 price target.
The initiation of coverage by a major firm like Cantor Fitzgerald typically influences investor perception. Despite the positive Overweight rating, the market may have reacted negatively due to expectations or other market conditions, leading to a short-term decline in SPRY's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100